An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

Trial Profile

An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs Rovalpituzumab tesirine (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TRINITY
  • Sponsors Stem CentRx
  • Most Recent Events

    • 10 Aug 2018 Planned End Date changed from 1 Jan 2020 to 1 Oct 2018.
    • 10 Aug 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Oct 2018.
    • 05 Jun 2018 Results of an interim analysis (n=199; Data cut-off: 6 Oct 2017) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top